1313.7.1 Boehringer Ingelheim Investigational Site
Biberach, Germany
NCT Number: NCT01707940
This trial investigates the influence of oral ketoconazole on the pharmacokinetics and safety of BI 144807.
Looking for future studies?
Notify Me18 year–50 year
Male
Interventional
Phase 1
Biberach, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ketoconazole 400 mg / day
BI144807 oral solution, intermediate dose
Time frame: 0 to 48 hours after administration
Time frame: 0 to 48 hours after administration
Time frame: 0 to 48 hours after administration
Boehringer Ingelheim
Industry
Relative Bioavailability of a Single Oral Dose of BI 144807 (Oral Solution) When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole (200 mg Tablet) in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Trial)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details